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There is increasing clinical evidence indicating that the immune system may either promote
or inhibit tumor progression. Several studies have demonstrated that tumors undergoing
remission are largely infiltrated by T lymphocytes [tumor-infiltrating lymphocytes (TILs)],
but on the other hand, several studies have shown that tumors may be infiltrated by TILs
endowed with suppressive features, suggesting thatTILs are rather associated with tumor
progression and unfavorable prognosis. γδ T lymphocytes are an important component
of TILs that may contribute to tumor immunosurveillance, as also suggested by promising
reports from several small phase-I clinical trials.Typically, γδ T lymphocytes perform effector
functions involved in anti-tumor immune responses (cytotoxicity, production of IFN-γ and
TNF-α, and dendritic cell maturation), but under appropriate conditions they may divert from
the typical Th1-like phenotype and polarize to Th2, Th17, and Treg cells thus acquiring the
capability to inhibit anti-tumor immune responses and promote tumor growth. Recent stud-
ies have shown a high frequency of γδT lymphocytes infiltrating different types of cancer,
but the nature of this association and the exact mechanisms underlying it remain uncertain
and whether or not the presence of tumor-infiltrating γδ T lymphocytes is a definite prog-
nostic factor remains controversial. In this paper, we will review studies of tumor-infiltrating
γδ T lymphocytes from patients with different types of cancer, and we will discuss their
clinical relevance. Moreover, we will also discuss on the complex interplay between cancer,
tumor stroma, and γδ T lymphocytes as a major determinant of the final outcome of the
γδT lymphocyte response. Finally, we propose that targeting γδT lymphocyte polarization
and skewing their phenotype to adapt to the microenvironment might hold great promise
for the treatment of cancer.
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γδ T LYMPHOCYTES: ANTIGEN RECOGNITION AND
EFFECTOR FUNCTIONS
T cells carrying the γδ T cell receptor (TCR) are important effec-
tor cells that may play a role in the anti-tumor immune response.
γδ Cells are not a homogeneous population of cells with a sin-
gle physiological role. Instead, ever increasing complexity in both
phenotype and function is being ascribed to γδ cell subsets from
various tissues and locations, both in mice and humans.
γδ T cells account for 1–5% of CD3+ T cells in the peripheral
blood, but constitute a major subset in other anatomic sites, such
as the intestine or the skin [here, however, only in the murine but
not in human skin (1)]. In the blood of most healthy individuals,
T cells expressing the Vδ2 gene paired with one particular Vγ9
chain (referred to as Vγ9Vδ2 T cells) account for 50 to >90% of
the γδ T cell population. In contrast, intestinal intraepithelial γδ
T cells frequently express the Vδ1 gene, which can associate with
different Vγ elements (1, 2). Vδ1 γδ T cells recognize the MHC
class I-related molecules MICA, MICB, and ULBPs, which are
expressed on epithelial cells by heat shock or oxidative stress and
are constitutively expressed to variable levels on many epithelial
and hematopoietic tumor cells (3, 4). It has been debated whether
MICA/MICB and ULBPs are directly recognized by the Vδ1 TCR
or, indirectly activate Vδ1 T cells upon binding to the stimulatory
natural killer (NK) receptor, NKG2D, which is also expressed by
the vast majority of γδ T cells.
Vγ9Vδ2 T cells recognize phosphoantigens (PAgs) without
requirement for antigen processing and presentation, and MHC
restriction. PAgs are pyrophosphates derived from the microbial
non-mevalonate isoprenoid biosynthesis pathway (5, 6). Struc-
turally related pyrophosphates are generated in eukaryotic cells
through the mevalonate pathway. Micromolar concentrations of
endogenous pyrophosphates are required for Vγ9Vδ2 T cell activa-
tion and such concentrations are achieved after cellular stress and
transformation (7). Given the cross-reactivity between microbial
and self PAgs, there is a great interest in elucidating how TCR sig-
naling can be induced by such small molecules. PAgs can directly
activate Vγ9Vδ2 T cells, but such activation is greatly enhanced
by monocytes and/or dendritic cells (DCs). Hence, either PAgs
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are presented as cargo to the reactive γδ TCR or their cellu-
lar processing somehow sensitizes cell recognition through the
engagement of the Vγ9Vδ2 TCR by stabilizing surface expression
of a TCR-binding molecules (8). A candidate molecule involved
in intracellular PAg processing is the F1-ATPase, which directly
binds the Vγ9Vδ2 TCR and interacts with ApppI, an adenosine
derivative of IPP (9). Moreover, it has been recently found that
PAg-induced Vγ9Vδ2 T cell activation requires butyrophilin 3A1
(BTN3A1) (10–12). Therefore, production of exogenous PAgs or
up-regulation of endogenous PAgs in human cells in response to
either infections or tumor transformation provokes Vγ9Vδ2 T cell
reactivity, albeit at substantially different sensitivity.
Intracellular levels of PAgs can be manipulated by drugs.
Aminobisphosphonates, such as zoledronic acid, which are in clin-
ical use for the treatment of osteoporosis and bone metastasis, are
potent inhibitors of the downstream enzyme of the mevalonate
pathway farnesyl pyrophosphate synthase, thereby leading to the
intracellular accumulation of upstream metabolites as IPP and in
consequence to Vγ9Vδ2 T cell activation (13, 14). On the contrary,
statins block the upstream enzyme hydroxymethylglutaryl-CoA
reductase and inhibits IPP production, inhibiting Vγ9Vδ2 T cell
activation (15).
Vγ9Vδ2 T cells express numerous molecules potentially associ-
ated with different stages of differentiation, migration, and func-
tions. Vγ9Vδ2 T cells include “naive” and “central memory” phe-
notypes (TNaive, CD45RA+CD27+; TCM, CD45RA−CD27+) that
home to secondary lymphoid organs, but lack immediate effec-
tor function, and “effector/memory” (TEM, CD45RA−CD27−)
and “terminally differentiated” (TEMRA, CD45RA+CD27−) phe-
notypes that home to sites of inflammation and display immediate
effector function (16).
While TNaive and TCM cells readily respond to PAgs stimulation,
T cells with effector memory (TEM) and terminally differenti-
ated effector memory (TEMRA) expand in response to homeo-
static cytokines as IL-15 (17) and differentiate in the presence
of polarizing cytokines (18). On activation, Vγ9Vδ2 cells can be
skewed toward distinct effector functions depending on polariz-
ing cytokines, in analogy to CD4 helper T cells. Typically, human
Vγ9Vδ2 T cells default toward type 1 cytokine production (γδ1),
but under appropriate culture conditions they divert from the typ-
icalγδ1 phenotype and polarize toγδ2 (19,20),γδ17 (21–23),γδFH
(24, 25), and γδreg cells (26). Such a broad plasticity emphasizes
the capacity of Vγ9Vδ2 T cells to influence the nature of immune
response to different challenges.
γδ T CELLS FOR TUMOR IMMUNOTHERAPY
The major goal of tumor immunotherapy is the induction of adap-
tive responses of B cells and MHC-restricted αβ T cells, particu-
larly CD8 cytotoxic T cells. Nonetheless, despite major advances
in this area, durable responses are rare and immunotherapy is not
yet an established modality to treat tumors. Furthermore, tumors
frequently develop strategies to escape immune responses (27, 28).
In contrast to αβ T cells, γδ T cells have unique features (see
Table 1), which makes them good candidates for effective tumor
immunotherapy. For instance, they lack MHC restriction, and do
not require co-stimulation. Therefore, common tumor antigens
without MHC restriction provide broader applicability of γδ T
Table 1 | Advantages of using γδ T cells for tumor immunotherapy.
The frequency of γδT cells is very high (1–5/102), compared to that of
Ag-specific αβT cells (1/105–106)
γδT cells can recognize and lyse a broad range of tumor cells and there is
no need to target tumor-specific Ags
γδT cells lack MHC restriction in antigen recognition
γδT cell activation does not require co-stimulatory signals (e.g., CD28)
mAb can be used in vivo to enhance γδT cell cytotoxicity (ADCC)
γδT cells seem to be devoid of GVH activity
FDA-approved drugs (Zoledronate, IL-2) available for γδT cell expansion
in vivo
Large scale ex vivo expansion of γδT cells and clinical grade sets for
purification
cells across a wide range of tumors and patients with diverse MHC
alleles. Moreover, γδ T cells display potent cytotoxic and anti-
tumor activity in vitro (29–33) and in xenograft models in vivo
(34, 35). Cytotoxicity of γδ T cells against tumor cells is associated
with increased production of PAgs (36), which is, at least, partly
due to the increased expression of hydroxymethylglutaryl-CoA
reductase, the rate limiting enzyme of the mevalonate pathway
(36). Moreover, intracellular levels of IPP can be manipulated
by aminobisphosphonates (13–15, 37–39), thereby leading to the
intracellular accumulation of IPP and in consequence to activa-
tion of Vγ9Vδ2 T cells (36). As above discussed, in addition to the
binding of the antigenic molecules to the reactive TCR, Vγ9Vδ2 T
cells express NK cell activating receptors such as NKG2D, which
recognizes target cells expressing MICA, MICB, and ULBPs (3, 4,
40, 41). These interactions may prove crucial in Vγ9Vδ2 T cell
recognition and killing of tumors of hematopoietic origin. In fact,
the expression levels of ULBP1 determine lymphoma susceptibil-
ity to Vγ9Vδ2 T cell-mediated cytolysis, highlighting a thus far
unique physiologic relevance for tumor recognition by Vγ9Vδ2 T
cells (42, 43).
After recognizing target cells via the TCR, or NKG2D, or both,
Vγ9Vδ2 T cells preferentially use the perforin/granzyme (44)
and/or TRAIL (45) pathways, as well as the Fas/FasL killing signal
(46), for cytotoxicity against target cells like tumor cells. In addi-
tion, activated Vγ9Vδ2 T cells secrete IFN-γ and TNF-α, which
have cytotoxic activity against tumor cells directly and indirectly
via stimulating macrophages and DCs (47–49).
Overall, the potent anti-tumor activity of Vγ9Vδ2 T cells and
their wide reactivity to several tumor cell types has led to the
exploration of their therapeutic potential. Two strategies have been
developed to apply the anti-tumor activities of Vγ9Vδ2 T cells to
cancer immunotherapy: (1) in vivo administration of compounds
that activate Vγ9Vδ2 T cells and (2) adoptive transfer of ex vivo-
expanded Vγ9Vδ2 T cells. Several small-sized clinical trials have
tested the efficacy of any of these two strategies in patients with
various tumor types and a recent meta-analysis based on data from
13 clinical trials including a total of 204 patients has demonstrated
that Vγ9Vδ2 T cell-based immunotherapy improves overall sur-
vival and, in view of its low toxicity grade (50), provides a proof of
principle for its utilization as adjuvant to conventional therapies.
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TUMOR-INFILTRATING γδ T CELLS AND THEIR CORRELATION
TO CANCER OUTCOME
Tumor-infiltrating leukocytes are an heterogeneous population of
immune cells that have been found in a wide variety of solid
tumors (51) and the extent of leukocyte infiltration has been
often associated with improved prognosis (52). However, there
is a limited number of studies regarding the contribution of indi-
vidual leukocyte subsets to survival. Tumor-infiltrating leukocytes
include cells of the myeloid lineage (granulocytes, macrophages,
and myeloid-derived suppressor cells) and several different lym-
phocyte subsets (T, B, and NK), each with different impact on
tumor progression. Results of mouse tumor models and human
cohort studies have suggested that any individual leukocyte pop-
ulation may correlate with poor or better prognostic factors,
such as tumor stage/grade, presence of metastasis, and disease-
free/overall survival. In general, infiltration by myeloid cells has
been associated with tumor progression, while the presence of
abundant T cells (particularly of the CD8 subset) is associated with
tumor regression and improved prognosis. However, the limits of
the immunohistochemical techniques largely used in retrospec-
tive clinical studies, have so far prevented a detailed descriptions
of different tumor-infiltrating leukocyte populations as well as
evaluation of their functional properties in the tumor microen-
vironment. For instance, tumor-infiltrating T lymphocytes may
be endowed with regulatory function and hence promote tumor
progression.
Several studies have shown that γδ T cells are present among
tumor-infiltrating lymphocytes (TILs) from patients affected by
different types of cancer, but their clinical relevance remains still
obscure because of conflicting results obtained.
In detail, there have been five relatively recent large studies,
which have correlated tumor-infiltrating γδ T cells with several
different clinical features:
Bialasiewicz et al. (53) evaluated by immunohistochemical
analysis TILs in 113 specimens from patients with necrotizing
choroidal melanoma. They detected TILs in 76% of samples and
γδ T cells,mainly of theVδ1 subset were present in 52% of samples.
Most notably, the presence of γδ T cells in tumors positively cor-
related with patient’s survival, indicating that tumor-infiltrating
γδ T cells are a prognostically favorable factor.
Inman et al. (54) assessed by immunohistochemical analysis
total γδ T cells in 248 renal cancer specimens and correlated these
values with clinicopathologic prognostic factors and cancer out-
come. They found that percentages of intratumoral γδ T cells
were usually very low (<1% of the CD3+ population) in nearly all
tested tumor specimens and did not correlate with any examined
prognostic factor or even with survival. Authors concluded that
the role of γδ T cells in renal cancer is questionable.
Ma et al. (55) examined by immunohistochemistry total γδ T
cells infiltrating breast cancer in specimens of 46 patients. γδ T
cells were detected in nearly all cancer patients (93%), but only
in 3% of normal breast specimen. Authors did not quantify the
percentages of intratumoral γδ T cells, but when an arbitrary
cut-off of nine γδ T cells per high magnification microscopic
field was used to define TIL-high (>9) and TIL-low (<9) groups,
authors found that γδ T cell numbers were positively correlated
with advanced tumor stages, HER2 expression status, and high
lymph node metastasis, but inversely correlated with relapse-free
survival and overall survival of patients. Multivariate and univari-
ate analysis of tumor-infiltrating γδ T cells and other prognostic
factors further suggested that intratumoral γδ T cells represented
the most significant independent prognostic factor for assessing
severity of breast cancer compared with the other known factors.
Authors concluded that tumor-infiltrating γδ T cells play a crucial
role in breast cancer progression and pathogenesis and may serve
as a valuable and independent prognostic biomarker for human
breast cancer.
Cordova et al. (56) studied the representation of tumor-
infiltrating γδ T cells from 74 patients with primary melanoma.
γδ T cells were the major subset among CD3+ T lymphocytes
and comprised equal percentages of Vδ1 and Vδ2 TEM or TEMRA
phenotypes. In this study, the presence of γδ T cells, and in partic-
ular the Vδ2 subset, among TILs significantly correlated with early
stage melanoma, while percentages of infiltrating Vδ1 T cells did
not correlate with any examined prognostic factor of melanoma.
Finally, Wu et al. (57) demonstrated that γδ T cells (γδ17) are
the major source of IL-17 in human colon cancer, with the majority
(80%) of the IL-17+ γδ T cells expressing Vδ1 and 20% express-
ing Vδ2. Importantly, analyzing 117 colon cancer samples, authors
found that γδ17 cell infiltration positively correlated with tumor
stages and other clinicopathological factors (tumor size, tumor
invasion, lymphatic and vascular invasion, lymph node metasta-
sis, and serum CEA levels), indicating that tumor-infiltrating γδ17
T cells are associated with tumor invasiveness and progression and
may thus represent a prognostic factor in human colon cancer.
TUMOR-INFILTRATING γδ T CELLS: WHAT ARE THEY AND
WHAT DO THEY DO ?
The above discussed findings that tumor-infiltratingγδ T cells cor-
relate with tumor remission, or with tumor progression or even
fail to correlate with any prognostic feature strongly suggest that
γδ T cells in the tumor microenvironment may play substantially
different functions; hence positive or negative correlation with
prognosis may depend on the specific γδ T cell subset/function
recruited at the tumor site. Furthermore, the net biologic effects
of γδ T cells may depend on the tumor type and the tumor site,
perhaps reflecting microenvironmental differences: for instance
TGF-β, which is abundantly secreted at the tumor site by tumor-
infiltrating macrophages or by tumor cells themselves, may favor
the differentiation of γδ cells with Treg-like properties, which in
turn inhibit anti-tumor immune responses.
Initial studies on the functional properties of tumor-infiltrating
γδ T cells were performed using polyclonal γδ T cell lines gener-
ated in vitro upon long term culture with mitogen/antigen and
IL-2: this approach was mainly due to the very low number of
γδ T cells recovered from tumor specimen and to the lack of
suitable techniques, which allowed precise detection of functional
markers. These studies have unequivocally demonstrated that ex
vivo-expanded γδ T cell lines and clones from renal, breast, lung,
ovary, colon, and pancreatic cancer efficiently kill stabilized tumor
cell lines and freshly isolated tumor cells and generally Vδ1 T cell
lines had the higher cytotoxic activity compared to Vδ2 T cell
lines (58–63). Accordingly, Cordova et al. (56) confirmed these
results using polyclonal γδ T cell lines derived from melanoma;
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both Vδ1 and Vδ2 T cell lines produced equal amounts of TNF-α
and IFN-γ, but while the majority (75%) of Vδ1 T cell lines exerted
potent cytotoxic activity against melanoma cell line in vitro, only
25% of the Vδ2 T cell lines showed appreciable lytic activity.
Therefore, based on their cytolytic activity and production of
cytokines with proven anti-tumor effect, tumor-infiltrating γδ T
cells have been long regarded as important players of the anti-
tumor immune response. However, both the failure to consistently
detect a positive correlation between the presence of γδ T cells in
the tumor microenvironment and the patient’s prognosis, as well
as the improvement of immunological techniques to detect func-
tional signatures even in very small tissue samples have subverted
the concept that γδ T cells are simply an important component
of resistance to cancer and suggested that their function may be
extremely pleiotropic and including either effector or suppressive
potential.
In 2007, Peng and colleagues (64) unexpectedly identified a
Vδ1+ population (which comprised over 95% of the totalγδT cells
population) among breast cancer-infiltrating lymphocytes capable
to suppress immune responses. In particular, Vδ1 cells inhibited
CD4 and CD8 T cell activation and impaired DC maturation and
function. Although the mechanisms responsible for the regulatory
activity of tumor-infiltrating Vδ1 cells was not investigated in that
paper, it seems to involve TLR8 signaling pathway, as suppression
was reversed by TLR8 ligands. Later on, the same group reported
(65) that breast cancer-infiltrating Vδ1 cells induced both T cell
and DC senescence and the senescent T cells and DCs in turn
became regulatory cells, thus determining amplification of the
immunosuppressive process. Interestingly, and surprisingly, accu-
mulation of regulatory Vδ1 cells in the context of breast cancer
(where they account for approximately 30% of the total lympho-
cyte population) is not due to proliferation of residentVδ1 cells but
to their recruitment mediated by IP-10 secreted by breast cancer
cells.
In addition to the above quoted studies on tumor-infiltrating
human regulatory γδ T cells, four recent reports, three in mice
and one in humans, have shed light on the regulatory role played
by IL-17-producing γδ T cells (γδ17) and have also defined the
underlying mechanisms.
Using a transplantable tumor mouse model, Wakita et al. (66)
observed that γδ T cells accounted for 25% of all TILs and selec-
tively produced IL-17 but not IFN-γ. Importantly, absence of
IL-17 caused inhibition of tumor growth, which correlated with a
reduced number of blood vessels within the tumor and reduced
expression levels of VEGF and Ang-2 in tumor cells. This indi-
cates that tumor-infiltrating γδ17 T cells promote angiogenesis,
and thus tumor growth.
A similar detrimental effect of IL-17 has been reported by
Ma and colleagues (67) in an hepatocellular carcinoma mouse
model. Similarly to the findings of Wakita et al., γδ T cells were the
major source of IL-17 amongst lymphocytes infiltrating hepato-
cellular carcinoma. In this model, absence of IL-17 reduced tumor
growth, while its administration promoted the growth of hepato-
cellular carcinoma. However, the mechanism responsible for the
anti-tumor activity of IL-17 was different from that reported by
Wakita and involved a reciprocal activatory interaction between
the γδ17 cells and MDSC, which was mediated by cancer cells:
in detail, γδ T cell-derived IL-17 induced CXCL5 production by
tumor cells, which in turn recruited MDSC to the tumor sites via
CXCL5/CXCR2-interaction. Once at the tumor site, IL-17 induced
production of IL-1β and IL-23 in MDSC, which amplify differen-
tiation of γδ17 cells. This positive feedback between γδ17 cells
and MDSC sustains immunosuppression and promotes tumor
growth.
The third mouse study by Silva Santos and colleagues (68) used
a transplantable peritoneal/ovarian cancer, and confirmed the cru-
cial role of γδ17 in promoting cancer growth. γδ17 accumulated in
the peritoneal cavity and were the main source of IL-17 also in this
model. γδ17 caused the recruitment at the tumor site of an uncon-
ventional population of small macrophages that expressed IL-17
receptor and a number of pro-tumor and pro-angiogenic mole-
cules amongst which VEGF and TGF-β, which promoted cancer
cell proliferation and tumor growth.
The fourth study on the participation of γδ17 cells in cancer was
performed by Wu et al. (57) in human colorectal cancer. In that
study, tumor-infiltratingγδT cell was the main source of IL-17 and
80% of the γδ17 cells expressed Vδ1. Of note however, γδ17 con-
stituted approximately 25% of all tumor-infiltrating Vδ1 cells and
co-produced TNF-α, IL-8, and GM-CSF. All these cytokines, in dif-
ferent combinations, caused recruitment (IL-8 and GM-CSF) and
survival, activation, and proliferation (TNF-α, IL-8, and IL-17)
of MDSC that in turn mediate immunosuppression and promote
tumor growth.
Altogether these results clearly demonstrate that γδ17 cells are
key mediators of tumor-associated immunosuppression thereby
influencing tumor progression.
HYPOTHESIS: TUMOR MICROENVIRONMENT AS THE
CRITICAL DETERMINANT OF TUMOR-INFILTRATING γδ T
CELL FATE
The conditions under which γδ T cells can contribute to tumor
control versus immune suppression need to be defined. There are
several theoretical possibilities to answer the fundamental ques-
tion of the molecular mechanisms that explain these two γδ T cell
phenotypes.
First, it is possible that genetic differences in tumor cells influ-
ence the host response, through the involvement of different path-
ways that are mutated or activated in a heterogeneous fashion and
that regulate the expression of immune system regulatory genes.
For instance, tumor cells with STAT3 activation show impaired
production of chemokines and cytokines, but increased pro-
duction of immunosuppressive factors and thus escape immune
recognition (69).
Second, it is possible that polymorphism of regulatory genes
might influence lymphocyte activation at the tumor site. For
instance, IRF5 polymorphism is associated with clinical response
to adoptively transferred TILs in melanoma patients (70).
Third, it is likely that exposure to certain pathogens or even
the intestinal microbiome could change the frequency, phenotype,
and functions of TILs. For instance, Wu et al. (57) showed that in
colon cancer patients, destruction of the epithelial barrier caused
by tumor development results in tumor invasion by commensal
bacteria (E. coli) and release of bacterial product, which promote
IL-23 production by DCs and γδ17 cell polarization in situ.
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Fourth, it is likely (and this is the possibility we favor) that
tumor microenvironment plays a key role. By definition, tumor
microenvironment is a complex network of different cell types,
soluble factors, signaling molecules, and extracellular matrix com-
ponents, which orchestrate the fate of tumor progression (71). In
fact, in addition to the tumor cells and to the several lymphoid and
myeloid cell types that infiltrate tumors, classical cellular compo-
nents of the solid tumor stromal microenvironment also influence
the host immune response. The tumor stroma consists of fibrob-
lasts, macrophages, and vascular endothelial cells, with variable
amounts of extracellular matrix, all of which contribute not only
as a support structure for tumor growth, but can also impair host
immune responses and likely contribute to the quality of immune
cell infiltration (71). We hypothesize (Figure 1) that, at early
stages of tumor development γδ T cells of the γδ1 type produc-
ing cytokines with proven anti-tumor activity (IFN-γ and TNF-α)
and equipped with cytotoxic potential either expand locally (Vδ1)
or are recruited at the tumor site from peripheral blood (Vδ2) and
may exert anti-tumor activity; however, with tumor progression,
factors produced in the microenvironment cause polarization of
γδ cells from γδ1 to γδ17 and γδreg, which instead promote
tumor progression. A plethora of cell types present in the tumor
microenvironment may actually provide the source of such γδ cells
polarizing factors.
For instance, colon cancer stem cells and tumor-associated
macrophages and fibroblasts produce huge amounts of TGF-β
(72) which, in combination with other cytokines present in the
microenvironment, contributes to polarization of γδ T cells to
γδ17 and γδreg.
Macrophages, DCs, and other myeloid cells, which are typically
found in the solid tumor microenvironment, produce IL-15, which
in combination with TGF-β determines γδreg polarization (26),
and IL-1β, IL-6, IL-23, and TGF-β, which in different combination
promote γδ17 Polarization (22).
Finally, it is also possible that those γδ T cells within TILs
equipped with anti-tumor activities die after antigenic activation
and the frequencies of γδreg, which would be less tumor reac-
tive or resistant to cell death then increase. Moreover, nitric oxide,
which is largely produced by MDSC in the tumor microenviron-
ment may contribute to apoptosis of γδ T cells induced by antigen
activation (73).
Once activated, γδreg and γδ17 amplify the immunoregula-
tory process in different ways (Figure 2): IL-17 promotes VEGF
production by cancer cells and macrophages, and CXCL5 pro-
duction by tumor cells which, in turn, recruited MDSC. An acti-
vatory cross-talk is then established at the tumor site between
MDSC and γδ17, by which IL-17 induces IL-1β and IL-23 pro-
duction by MDSC and these cytokines promote further differ-
entiation and activation of γδ17 T cells. Finally, γδreg produce
IL-10 and TGF-β, which act on several cellular targets to pro-
mote immunosuppression at the tumor site and favor tumor
progression.
Several recent discoveries have been made toward under-
standing the biological effects of cytokines, particularly TGF-
β, produced in the tumor microenvironment that can polar-
ize many arms of the immune system. Thus, and similarly to
what we propose to occur for γδ cells, cytokines present in the
tumor microenvironment induce DCs to acquire a tolerogenic
FIGURE 1 | Polarization of γδ T cells in the tumor microenvironment. Our
working hypothesis for the recruitment of γδ T cells with different phenotypes
and functions into the tumor site. At early stages of tumor development
tumor cells produce chemokines, which recruit γδ T cells of the γδ1 type
equipped with anti-tumor activities (IFN-γ and TNF-α production and cytotoxic
potential). It is speculated that during progression, tumors have denser
stroma (ECM, extracellular matrix) and alternative DCs, myeloid, or
macrophage (MΦ) populations, which produce cytokines that accumulate in
the tumor microenvironment and cause polarization of γδ cells from γδ1 to
γδ17 and γδreg.
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FIGURE 2 | IL-17-dependent cellular interactions into the tumor
microenvironment. γδ17 release IL-17, which mediates several effects: it
promotes VEGF production by cancer cells and macrophages, thus causing
tumor vascularization and favoring metastasis; it promotes TGF-β production
by macrophages (MΦ) thus causing tumor growth; it promotes CXCL5
production by tumor cells which, in turn, recruited MDSC. Then a mutual
stimulatory circuit is established between MDSC and γδ17, which involves
IL-17, IL-1β, and IL-23, which leads to further differentiation and activation of
γδ17 T cells and amplification of the immunosuppressive process.
phenotype, convert N1 neutrophils to a N2 phenotype and pro-
mote the recruitment of M2 over M1 macrophages. Within the
tumor microenvironment, cytokines also inhibit Th1 and CD8
CTL functions and probably promote a shift toward Th2, Th17,
and Tc17 differentiation and convert CD4 effector T cells to
induced Treg (iTReg) cells. For a systematic review on the polar-
ization of immune cells in the tumor microenvironment see in
Ref. (74).
CONCLUSION AND PERSPECTIVES
The mutual and interdependent interaction between tumor and
its microenvironment is a crucial topic in cancer research and
therapy, as recently demonstrated by the finding that targeting
stromal factors could improve efficacies of current therapeu-
tics and prevent metastasis. For instance, combinatorial therapy
with an agonistic mAb against CD40 and standard gemcitabine
chemotherapy, proved unexpectedly efficient in pancreatic cancer
(75). In this system, the anti-CD40 mAb caused massive recruit-
ment of macrophages at the tumor site, which caused severe
disruption of the tumor stroma thus allowing increased con-
centrations of gemcitabine to accumulate to the tumor site (75).
Similarly, the identification of defined immunosuppressive path-
ways in the tumor microenvironment has pointed toward ther-
apeutic targets that are amenable to clinical intervention: these
include, for instance, mAbs to PD-1 or PD-L, CTLA-4, CD25,
and small-molecule inhibitors that block IDO enzymatic activ-
ity [reviewed in Ref. (76)]. These novel strategies must be kept
in mind when designing γδ T cell-based therapy. Moreover radi-
ation therapy, low dose traditional chemotherapeutic drugs and
aminobisphosphonates not only sensitize tumor cells to immune
recognition and killing, but also modulate the tumor microen-
vironment and contribute to the therapeutic effect (77–80): for
instance, zoledronic acid at clinically achievable doses repolarizes
tumor-associated macrophages to a M1 phenotype and reduces
the number of MDSC (81).
γδ T cell-based immunotherapy is emerging to be a powerful
treatment option for patients with different types of tumors. It
includes the in vivo activation of γδ cells or the adoptive trans-
fer of ex vivo-expanded γδ cells. Although we have no evidence
of the fate of the activated γδ cells and the long term effects of
the γδ cell-based therapies in preclinical and clinical studies, it is
reasonable to predict that the tumor microenvironment plays an
indispensable role in limiting the effectiveness of γδ T cell-based
immunotherapies. Additionally, the local expansion of adoptively
transferred γδ T cells has to be increased to achieve higher T cell
numbers at the tumor site.
Therefore, combination regimens consisting of γδ T cell-based
therapies and strategies aimed to circumvent the negative impact
of the tumor microenvironment onto γδ T cells and induce γδ
T cell repolarization, may prove efficacious and achieve clinical
benefit in patients with different types of tumor.
ACKNOWLEDGMENTS
This work was supported by grants from the Ministry of Health
“Ricerca Finalizzata 2007” (to Franceso Dieli) and the Univer-
sity of Palermo. Elena Lo Presti is a student of the International
Ph.D. Program in Immunopharmacology at the University of
Palermo.
REFERENCES
1. Hayday AC. γδ T cells: a right time and a right place for a conserved third way
of protection. Annu Rev Immunol (2000) 18:975–1026. doi:10.1146/annurev.
immunol.18.1.975
2. Bonneville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend
of innate programming and acquired plasticity. Nat Rev Immunol (2010)
10:467–78. doi:10.1038/nri2781
3. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC
molecules by intestinal epithelial γδ T cells. Science (1998) 279:1737–40.
doi:10.1126/science.279.5357.1737
4. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vδ1
T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic
B cells and up-regulated by trans-retinoic acid. Cancer Res (2004) 64:9172–9.
doi:10.1158/0008-5472.CAN-04-2417
5. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR. Natural and
synthetic non-peptide antigens recognized by human γδ T cells. Nature (1995)
75:155–8. doi:10.1038/375155a0
6. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wiesner J, Jomaa H. Microbial iso-
prenoid biosynthesis and humanγδT cell activation. FEBS Lett (2003) 544:4–10.
doi:10.1016/S0014-5793(03)00483-6
7. Sireci G, Espinosa E, Di Sano C, Dieli F, Fournié JJ, Salerno A. Differ-
ential activation of human γδ cells by nonpeptide phosphoantigens. Eur J
Immunol (2001) 31:1628–35. doi:10.1002/1521-4141(200105)31:5<1628::AID-
IMMU1628>3.0.CO;2-T
8. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to
immunology. Nat Rev Immunol (2013) 13:88–100. doi:10.1038/nri3384
9. Scotet E, Martinez LO, Grant E, Barbaras R, Jeno P, Guiraud M, et al.
Tumor recognition following Vγ9Vδ2 T cell receptor interactions with a
Frontiers in Immunology | T Cell Biology November 2014 | Volume 5 | Article 607 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lo Presti et al. γδ T cells in tumor immunity
surface F1-ATPase-related structure and apolipoprotein A-I. Immunity (2005)
22:71–80. doi:10.1016/j.immuni.2004.11.012
10. Vavassori S, Kumar A, Wan GS, Ramanjaneyulu GS, Cavallari M, El Daker S,
et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human
γδ T cells. Nat Immunol (2013) 14:908–16. doi:10.1038/ni.2665
11. Harly C, Guillaume Y, Nedellec S, Peigné CM, Mönkkönen H, Mönkkö-
nen J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular
stress sensing by a major human γδ T-cell subset. Blood (2012) 120:2269–79.
doi:10.1182/blood-2012-05-430470
12. Sandstrom A, Peigné CM, Léger A, Crooks JE, Konczak F, Gesnel MC, et al.
The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to
mediate activation of human Vγ9Vδ2 T cells. Immunity (2014) 40:490–500.
doi:10.1016/j.immuni.2014.03.003
13. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson
K. Peripheral blood monocytes are responsible for γδ T cell activation induced
by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2009)
144:245–50. doi:10.1111/j.1365-2141.2008.07435.x
14. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, et al.
Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate
synthase unveils recognition of tumor cells by Vγ9Vδ2 T cells. J Immunol (2009)
182:8118–24. doi:10.4049/jimmunol.0900101
15. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T
cell receptor γδ T cells recognize endogenous mevalonate metabolites in tumor
cells. J Exp Med (2003) 197:163–8. doi:10.1084/jem.20021500
16. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differ-
entiation of effector/memory Vδ2 T cells and migratory routes in lymph
nodes or inflammatory sites. J Exp Med (2003) 198:391–7. doi:10.1084/jem.
20030235
17. Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F, et al.
Differential requirements for antigen or homeostatic cytokines for proliferation
and differentiation of human Vγ9Vδ2 naive, memory and effector T cell subsets.
Eur J Immunol (2005) 35:1764–72. doi:10.1002/eji.200525983
18. Caccamo N, Todaro M, Sireci G, Meraviglia S, Stassi G, Dieli F. Mechanisms
underlying lineage commitment and plasticity of human γδ T cells. Cell Mol
Immunol (2013) 10:30–4. doi:10.1038/cmi.2012.42
19. Sireci G, Champagne E, Fournié JJ, Dieli F, Salerno A. Patterns of phosphoanti-
gen stimulation of human Vγ9Vδ2 T cell clones include Th0 cytokines. Hum
Immunol (1997) 58:70–82. doi:10.1016/S0198-8859(97)00211-5
20. Wesch D, Glatzel A, Kabelitz D. Differentiation of resting human periph-
eral blood γδ T cells toward Th1- or Th2-phenotype. Cell Immunol (2001)
212:110–7.
21. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the differen-
tiation and expansion of IL-17A- and IL-22-producing human Vγ9Vδ2 T cells.
J Immunol (2010) 184:7268–80. doi:10.4049/jimmunol.1000600
22. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al.
Differentiation, phenotype and function of interleukin-17-producing human
Vγ9Vδ2 T cells. Blood (2011) 118:129–38. doi:10.1182/blood-2011-01-331298
23. Fenoglio D, Poggi A, Catellani S, Battaglia F, Ferrera A, Setti M, et al. Vδ1 T lym-
phocytes producing IFN-γ and IL-17 are expanded in HIV-1-infected patients
and respond to Candida albicans. Blood (2009) 113:6611–8. doi:10.1182/blood-
2009-01-198028
24. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of
human γδ T cells to provide B-cell help. Eur J Immunol (2012) 42:110–9.
doi:10.1002/eji.201142017
25. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regu-
lates the differentiation of a human γδ T cell subset equipped with B cell helper
activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940
26. Casetti R, Agrati C, Wallace M, Sacchi A, Martini F, Martino A, et al. TGF-β1 and
IL-15 Induce FOXP3+ γδ regulatory T cells in the presence of antigen stimula-
tion. J Immunol (2009) 183:3574–7. doi:10.4049/jimmunol.0901334
27. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immu-
noediting: the roles of immunity in suppressing tumor development and shap-
ing tumor immunogenicity. Adv Immunol (2006) 90:1–50. doi:10.1016/S0065-
2776(06)90001-7
28. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunother-
apy for cancer: building on success. Nat Rev Immunol (2006) 6:383–93.
doi:10.1038/nri1842
29. Kunzmann V, Bauer E, Feurle J, Weihinger F, Torny HP, Wilhelm M. Stimulation
of γδT cells by aminobisphosphonates and induction of anti plasma cell activity
in multiple myeloma. Blood (2000) 86:384–92.
30. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, et al.
Vγ9Vδ2 T cell response to colon carcinoma cells. J Immunol (2005) 175:5481–8.
doi:10.4049/jimmunol.175.8.5481
31. Belmant C, Decise D, Fournie JJ. Phosphoantigens and aminobisphosphonates:
new leads targeting γδ T lymphocytes for cancer immunotherapy. Drug Discov
Today Ther Strateg (2006) 3:17–23. doi:10.1016/j.ddstr.2006.02.001
32. Liu Z, Guo BL, Gehrs BC, Nan L, Lopez RD. Ex vivo expanded human Vγ9Vδ2
γδ+ T cells mediate innate antitumor activity against human prostate cancer
cells in vitro. J Urol (2005) 173:1552–6. doi:10.1097/01.ju.0000154355.45816.0b
33. Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, et al. Phos-
phostim activated γδ T cells kill autologous metastatic renal cell carcinoma. J
Immunol (2005) 174:1338–47. doi:10.4049/jimmunol.174.3.1338
34. Kabelitz D, Wesch D, Pitters E, Zoller M. Characterization of tumor reactivity of
human Vγ9Vδ2 γδT cells in vitro and in SCID mice in vivo. J Immunol (2004)
173:6767–76. doi:10.4049/jimmunol.173.11.6767
35. D’Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al.
Vγ9Vδ2 T lymphocytes efficiently recognize and kill zoledronate-sensitized,
imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
J Immunol (2010) 184:3260–8. doi:10.4049/jimmunol.0903454
36. Harwood HJ Jr, Alvarez IM, Noyes WD, Stacpoole PW. In vivo regulation of
human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased
enzyme protein concentration and catalytic efficiency in human leukemia and
lymphoma. J Lipid Res (1991) 32:1237–52.
37. Kunzmann V, Bauer E, Wilhelm M. γδ T-cell stimulation by pamidronate. N
Engl J Med (1999) 340:737–8. doi:10.1056/NEJM199903043400914
38. Girlanda S, Fortis C, Belloni D, Ferrero E, Ticozzi P, Sciorati C, et al. MICA
expressed by multiple myeloma and monoclonal gammopathy of undetermined
significance plasma cells co-stimulates pamidronate-activated γδ lymphocytes.
Cancer Res (2005) 65:7502–8. doi:10.1158/0008-5472.CAN-05-0731
39. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, et al. Induction
of γδT-lymphocyte effector functions by bisphosphonate zoledronic acid in can-
cer patients in vivo. Blood (2003) 102:2310–1. doi:10.1182/blood-2003-05-1655
40. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, et al. MICA engagement
by human Vγ9Vδ2 T cells enhances their antigen dependent effector function.
Immunity (2001) 15:83–93. doi:10.1016/S1074-7613(01)00168-6
41. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann
T. Activation of Vγ9Vδ2 T cells by NKG2D. J Immunol (2005) 175:2144–51.
doi:10.4049/jimmunol.175.4.2144
42. Lanca T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C,
et al. The MHC class Ib protein ULBP1 is a nonredundant determinant
of leukemia/lymphoma susceptibility to γδ T-cell cytotoxicity. Blood (2010)
115:2407–11. doi:10.1182/blood-2009-08-237123
43. Gomes AQ, Correia DV, Grosso AR, Lança T, Ferreira C, Lacerda JF, et al. Identi-
fication of a panel of ten cell surface protein antigens associated with immuno-
targeting of leukemias and lymphomas by peripheral blood γδ T cells. Haema-
tologica (2010) 95:1397–404. doi:10.3324/haematol.2009.020602
44. Dieli F, Troye-Blomberg M, Ivanyi J, Fournie M, Bonneville MA, Peyrat G,
et al. Granulysin dependent killing of intracellular and extracellular Mycobac-
terium tuberculosis by Vγ9Vδ2 T lymphocytes. J Infect Dis (2001) 184:1082–5.
doi:10.1086/323600
45. Vermijlen D, Ellis P, Langford C, Klein A, Engel R, Willimann K, et al. Distinct
cytokine driven responses of activated blood γδ T cells: insights into unconven-
tional T cell pleiotropy. J Immunol (2007) 178:4304–14. doi:10.4049/jimmunol.
178.7.4304
46. Dalton JE, Howell G, Pearson J, Scott P, Carding SR. Fas-Fas ligand interactions
are essential for the binding to and killing of activated macrophages by γδ. J
Immunol (2004) 173:3660–7. doi:10.4049/jimmunol.173.6.3660
47. Ismaili J, Olislagers V, Poupot R, Fournie JJ, Goldman M. Human γδ T
cells induce dendritic cell maturation. Clin Immunol (2002) 103:296–302.
doi:10.1006/clim.2002.5218
48. Conti L, Casetti R, Cardone M,Varano B, Martino A, Belardelli F, et al. Reciprocal
activating interaction between dendritic cells and pamidronate-stimulated γδ T
cells: role of CD86 and inflammatory cytokines. J Immunol (2005) 174:252–60.
doi:10.4049/jimmunol.174.1.252
www.frontiersin.org November 2014 | Volume 5 | Article 607 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lo Presti et al. γδ T cells in tumor immunity
49. Devilder MC, Maillet S, Bouyge-Moreau I, Donnadieu E, Bonneville M, Scotet E.
Potentiation of antigen-stimulatedVγ9Vδ2 T cell cytokine production by imma-
ture dendritic cells (DC) and reciprocal effect on DC maturation. J Immunol
(2006) 176:1386–93. doi:10.4049/jimmunol.176.3.1386
50. Buccheri S, Guggino G, Caccamo N, Li Donni P, Dieli F. Efficacy and safety of
γδ T cell-based tumor immunotherapy: a meta-analysis. J Biol Regul Homeost
Agents (2014) 28:81–90.
51. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic
influence of tumour-infiltrating lymphocytes in cancer: a systematic review with
meta-analysis. Br J Cancer (2011) 105:93–103. doi:10.1038/bjc.2011.189
52. Sasada T, Suekane S. Variation of tumor-infiltrating lymphocytes in human
cancers: controversy on clinical significance. Immunotherapy (2011) 3:1235–51.
doi:10.2217/imt.11.106
53. Bialasiewicz AA, Ma JX, Richard G. αβ- and γδ TCR+ lymphocyte infiltra-
tion in necrotising choroidal melanomas. Br J Ophthalmol (1999) 83:1069–73.
doi:10.1136/bjo.83.9.1069
54. Inman BA, Frigola X, Harris KJ, Kuntz SM, Lohse CM, Leibovich BC, et al.
Questionable relevance of γδ T lymphocytes in renal cell carcinoma. J Immunol
(2008) 180:3578–84. doi:10.4049/jimmunol.180.5.3578
55. Ma C, Zhang Q, Ye J, Wang F, Zhang Y, Wevers E, et al. Tumor-infiltrating γδ T
lymphocytes predict clinical outcome in human breast cancer. J Immunol (2012)
189:5029–36. doi:10.4049/jimmunol.1201892
56. Cordova A, Toia F, La Mendola C, Orlando V, Meraviglia S, Rinaldi G, et al.
Characterization of human γδ T lymphocytes infiltrating primary malignant
melanomas. PLoS One (2012) 7:e49878. doi:10.1371/journal.pone.0049878
57. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. γδ T17 cells promote the accumu-
lation and expansion of myeloid-derived suppressor cells in human colorectal
cancer. Immunity (2014) 40:785–800. doi:10.1016/j.immuni.2014.03.013
58. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-
associated expression and recognition by tumor-derived γδ T cells of MICA and
MICB. Proc Natl Acad Sci U S A (1999) 96:6879–84. doi:10.1073/pnas.96.12.6879
59. Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-
infiltrating γδ T lymphocytes. Int Arch Allergy Immunol (2001) 125:256–63.
doi:10.1159/000053824
60. Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F.
Selective lysis of autologous tumor cells by recurrent γδ tumor-infiltrating lym-
phocytes from renal carcinoma. J Immunol (1995) 154:3932–40.
61. Ferrarini M, Heltai S, Pupa SM, Mernard S, Zocchi R. Killing of laminin receptor-
positive human lung cancers by tumor infiltrating lymphocytes bearing γδ+
T-cell receptors. J Natl Cancer Inst (1996) 88:436–41. doi:10.1093/jnci/88.7.436
62. Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, et al. Human
intestinal Vδ1+ lymphocytes recognize tumor cells of epithelial origin. J Exp
Med (1996) 183:1681–96. doi:10.1084/jem.183.4.1681
63. Kitayama J, Atomi Y, Nagawa H, Kuroda A, Mutoh T, Minami M, et al. Func-
tional analysis of TCR γδ+ T cells in tumour-infiltrating lymphocytes (TIL) of
human pancreatic cancer. Clin Exp Immunol (1993) 93:442–7. doi:10.1111/j.
1365-2249.1993.tb08198.x
64. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating
γδ T cells suppress T and dendritic cell function via mechanisms controlled
by a unique toll-like receptor signaling pathway. Immunity (2007) 27:334–48.
doi:10.1016/j.immuni.2007.05.020
65. Ye J, Ma C, Hsueh EC, Eickhoff CS, Zhang Y, Varvares MA, et al. Tumor-
derived γδ regulatory T cells suppress innate and adaptive immunity through
the induction of immunosenescence. J Immunol (2013) 190:2403–14. doi:10.
4049/jimmunol.1202369
66. Wakita D, Sumida K, Iwakura Y, Nishikawa H, Ohkuri T, Chamoto K, et al.
Tumor-infiltrating IL-17-producing γδT cells support the progression of tumor
by promoting angiogenesis. Eur J Immunol (2010) 40:1927–37. doi:10.1002/eji.
200940157
67. Ma S, Cheng Q, Cai Y, Gong H, Wu Y, Yu X, et al. IL-17A produced by γδ T
cells promotes tumor growth in hepatocellular carcinoma. Cancer Res (2014)
74:1969–82. doi:10.1158/0008-5472.CAN-13-2534
68. Rei M, Gonçalves-Sousa N, Lança T, Thompson RG, Mensurado S, Balkwill FR,
et al. Murine CD27- Vγ6+ γδ T cells producing IL-17A promote ovarian cancer
growth via mobilization of protumor small peritoneal macrophages. Proc Natl
Acad Sci U S A (2014) 111:E3562–70. doi:10.1073/pnas.1403424111
69. Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, et al. STAT3 activ-
ity in melanoma cells affects migration of immune effector cells and nitric
oxide-mediated antitumor effects. J Immunol (2005) 174:3925–31. doi:10.4049/
jimmunol.174.7.3925
70. Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R,
et al. Impact of the CCR5 gene polymorphism on the survival of metastatic
melanoma patients receiving immunotherapy. Cancer Immunol Immunother
(2008) 57:685–91. doi:10.1007/s00262-007-0407-z
71. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M, Stassi G. Tumor and its
microenvironment: a synergistic interplay. Semin Cancer Biol (2013) 23:522–32.
doi:10.1016/j.semcancer.2013.08.007
72. Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al.
CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving
colon cancer metastasis. Cell Stem Cell (2014) 14:342–56. doi:10.1016/j.stem.
2014.01.009
73. Atre N, Thomas L, Mistry R, Pathak K, Chiplunkar S. Role of nitric oxide in
heat shock protein induced apoptosis of gammadeltaT cells. Int J Cancer (2006)
119:1368–76. doi:10.1002/ijc.21966
74. Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P. The polarization of
immune cells in the tumour environment by TGFβ. Nat Rev Immunol (2010)
10:554–67. doi:10.1038/nri2808
75. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, et al.
CD40 agonists alter tumor stroma and show efficacy against pancreatic car-
cinoma in mice and humans. Science (2011) 331:1612–6. doi:10.1126/science.
1198443
76. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor
microenvironment. Nat Immunol (2013) 14:1014–22. doi:10.1038/ni.2703
77. Burnette B, Fu YX, Weichselbaum RR. The confluence of radiotherapy and
immunotherapy. Front Oncol (2012) 2:143. doi:10.3389/fonc.2012.00143
78. Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F. Combining conventional
chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating
cells. Oncoimmunology (2013) 2:e25821. doi:10.4161/onci.25821
79. Todaro M, D’Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S,
et al. Efficient killing of human colon cancer stem cells by γδ T lymphocytes. J
Immunol (2009) 182:7287–96. doi:10.4049/jimmunol.0804288
80. Santolaria T, Robard M, Léger A, Catros V, Bonneville M, Scotet E. Repeated
systemic administrations of both aminobisphosphonates and human Vγ9Vδ2
T cells efficiently control tumor development in vivo. J Immunol (2013)
191:1993–2000. doi:10.4049/jimmunol.1300255
81. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, et al. Zole-
dronic acid repolarizes tumor-associated macrophages and inhibits mammary
carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med (2010)
14:2803–15. doi:10.1111/j.1582-4934.2009.00926.x
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 14 October 2014; paper pending published: 05 November 2014; accepted: 12
November 2014; published online: 24 November 2014.
Citation: Lo Presti E, Dieli F and Meraviglia S (2014) Tumor-infiltrating γ δ T lym-
phocytes: pathogenic role, clinical significance, and differential programing in the tumor
microenvironment. Front. Immunol. 5:607. doi: 10.3389/fimmu.2014.00607
This article was submitted to T Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Lo Presti, Dieli and Meraviglia. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | T Cell Biology November 2014 | Volume 5 | Article 607 | 8
